Clinical trial · Interventional
MRS and 11C-methionine PET/CT in the Diagnosis of Glioma
Combination of 11C-MET PET and MRS in the Diagnosis of Glioma.
NCT03009318CI-TRIAL-00032421completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tumors are confirmed by surgery and pathology | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- MRS imaging and 11C-MET PET/CT
- description
- Each patient underwent both MRS and MET PET before surgery.
- interventionNames
- Other: tumors are confirmed by surgery and pathology
Primary outcomes (1)
- measure
- Sensitivity of the combination of MRS and 11C-MET PET/CT
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- The relationship between 11C-MET PET/CT results and molecular pathogeneses
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI 2. No surgery, chemotherapy or radiotherapy history 3. All patients gave written informed consent. Exclusion Criteria: 1. Patients with infratentorial Neoplasms 2. Patients with enhancing supratentorial lesions 3. Recurrent gliomas after surgery 4. Primary gliomas with history of radiotherapy or chemotherapy 5. History of malignant tumours at any body site 6. Inability to give informed consent
References
Publications (12)
- BACKGROUNDOstrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct;16 Suppl 4(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223. No abstract available. PMID 25304271
- BACKGROUNDFouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ. The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):457-79. doi: 10.1007/s11060-015-1908-9. Epub 2015 Nov 3. PMID 26530262
- BACKGROUNDWang W, Hu Y, Lu P, Li Y, Chen Y, Tian M, Yu L. Evaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis. PLoS One. 2014 Nov 13;9(11):e112577. doi: 10.1371/journal.pone.0112577. eCollection 2014. PMID 25393009
- BACKGROUNDMartinez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging. 2009 Dec;53(6):618-30. PMID 20016453
- BACKGROUNDGuo J, Yao C, Chen H, Zhuang D, Tang W, Ren G, Wang Y, Wu J, Huang F, Zhou L. The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien). 2012 Aug;154(8):1361-70; discussion 1370. doi: 10.1007/s00701-012-1418-x. Epub 2012 Jun 23. PMID 22729482
- BACKGROUNDYamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, Tominaga A, Takeshima Y, Sugiyama K, Kurisu K. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma. J Neurosurg. 2015 Jun;122(6):1370-9. doi: 10.3171/2014.9.JNS14106. Epub 2015 Mar 6. PMID 25748300